A clinical trial record update concerning teduglutide was posted on September 23, 2026. The registry, titled "Registry for Participants With Short Bowel Syndrome," is listed under identifier NCT01990040. According to the update, the study status is now active, not recruiting. No phase designation was provided for this registry entry. The record does not include any results, findings, or efficacy data as of this update. This entry reflects a status change only, indicating the registry continues to follow enrolled participants without adding new ones at this time.
Teduglutide is an approved therapy, and this registry appears designed to gather longer-term observational data from people with short bowel syndrome. As stated in the record, no new participants are currently being recruited into the study. Readers should note that a status update of this kind does not indicate trial results, safety findings, or treatment outcomes. It simply reflects where the study stands administratively as of the date reported.
For additional context on teduglutide, including its approved use and general background, readers can consult the compound overview.